Bin | SNP ID | SNP in gene | LD (r2 with rs1800795) | Rate of FEV1 decline study in the LHS | COPD case-control study in the NETT-NAS | |||||||
LHS | NETT-NAS | Fast decline MAF % | Non-decline MAF % | p Value‡ genotype based | p Value‡ additive | NETT MAF % | NAS MAF % | p Value§ genotype-based | p Value§ additive | |||
1 | rs1800797† | -598G/A | NA | 0.93 | 0.41 | 0.35 | 0.06 | 0.02 | ||||
1 | rs1800795*† | -174G/C | – | – | 0.45 | 0.40 | 0.006 | 0.041 | 0.42 | 0.36 | 0.03 | 0.01 |
1 | rs2069832† | 615A/G | NA | 0.98 | 0.42 | 0.37 | 0.10 | 0.09 | ||||
1 | rs1474348† | 1090G/C | NA | 0.97 | 0.41 | 0.36 | 0.10 | 0.04 | ||||
1 | rs1474347† | 1306G/T | NA | 0.98 | 0.42 | 0.36 | 0.06 | 0.03 | ||||
2 | rs1554606*† | 1889G/T | 0.84 | 0.87 | 0.47 | 0.43 | 0.011 | 0.103 | 0.44 | 0.38 | 0.02 | 0.01 |
2 | rs2069845* | 3331G/A | 0.89 | NA | 0.47 | 0.42 | 0.007 | 0.078 | ||||
3 | rs2069825* | -1479CT/– | 0.90 | NA | 0.44 | 0.37 | <0.001 | 0.023 | ||||
4 | rs2069840*† | 1754C/G | 0.36 | 0.33 | 0.32 | 0.37 | 0.005 | 0.064 | 0.35 | 0.36 | 0.30 | 0.70 |
5 | rs1818879* | 5909G/A | 0.32 | NA | 0.29 | 0.34 | 0.012 | 0.035 | ||||
6 | rs2069827*† | -1363G/T | 0.12 | 0.14 | 0.08 | 0.08 | 0.786¶ | 0.669 | 0.09 | 0.09 | 0.90 | 0.40 |
Other | rs2069849† | 4338C/T | NA | 0.02 | 0.03 | 0.02 | 0.20 | 0.20 |
COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 s; LD, linkage disequilibrium; LHS, Lung Health Study; MAF, minor allele frequency; NAS, Normative Aging Study; NETT, National Emphysema Treatment Trial; SNP, single nucleotide polymorphism.
*Genotyped in the LHS.
†Genotyped in the NETT-NAS.
‡Adjustment for confounding factors such as age, gender, pack-years of smoking and research centre.
§As the NAS controls were uniformly male smokers with normal lung function, the models were adjusted for age and pack-years.
¶The p values were from a dominant genetic model because the minor allele frequency of this SNP was very low.